Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Balfour Beatty CEO to step down after 10 years

(Sharecast News) - Infrastructure group Balfour Beatty has announced that its chief executive of 10 years Leo Quinn is to step down later this year. Under his leadership, Quinn is said to have "transformed Balfour Beatty into a strong, resilient Group, setting it firmly on a trajectory of profitable growth", according to chair Charles Allen.

During the past decade, Balfour Beatty has halved its debt position to £371m and delivered total shareholder returns of 261%, more than three times the average of the FTSE 250 index, the company said.

In a statement on Wednesday, the company said it has appointed Philip Hoare, currently the chief operating officer of Toronto-listed engineering services and nuclear enterprise AtkinsRéalis, as Quinn's replacement.

Hoare has been in his current role for a year, having previously served as CEO of Atkins in the UK and Europe, then as president of the group's engineering services business.

He will join the board in September, with Quinn continuing in an advisory capacity for "several months", Balfour Beatty said.

"I am delighted Philip will join the group as chief executive. The selection process made clear that his depth of industry knowledge and his experience in delivering a profitable growth strategy across multiple geographies make him the ideal person to drive forward the group's success in our chosen markets," Allen said.

Balfour Beatty's shares were down 1.2% at 450p by 0814 GMT.

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.